Your Biopharmaceutical Development and Manufacturing Partner

Soligenix Executes Option Agreement with University of Colorado on Thermostable Vaccine Technology

PRNewswire - November 2009

Soligenix, Inc. received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), and has formed a consortium to develop thermostable vaccine technology. Soligenix will partner with academic institutions, including Nanotherapeutics...

Full Article

Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.